menu
    • menu
    [{"orgOrder":0,"company":"Bioeq IP AG","sponsor":"Formycon","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"IL-12\/IL-23","graph1":"Dermatology","graph2":"Phase III","graph3":"Bioeq IP AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bioeq IP AG \/ Bioeq","highestDevelopmentStatusID":"10","companyTruncated":"Bioeq IP AG \/ Bioeq"},{"orgOrder":0,"company":"Bioeq IP AG","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bioeq IP AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bioeq IP AG \/ Bioeq","highestDevelopmentStatusID":"12","companyTruncated":"Bioeq IP AG \/ Bioeq"},{"orgOrder":0,"company":"Bioeq IP AG","sponsor":"Coherus Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bioeq IP AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bioeq IP AG \/ Bioeq IP AG","highestDevelopmentStatusID":"12","companyTruncated":"Bioeq IP AG \/ Bioeq IP AG"},{"orgOrder":0,"company":"Bioeq IP AG","sponsor":"Coherus Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"POLAND","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bioeq IP AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bioeq IP AG \/ Coherus Biosciences","highestDevelopmentStatusID":"12","companyTruncated":"Bioeq IP AG \/ Coherus Biosciences"},{"orgOrder":0,"company":"Bioeq IP AG","sponsor":"Formycon","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Bioeq IP AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bioeq IP AG \/ Formycon","highestDevelopmentStatusID":"10","companyTruncated":"Bioeq IP AG \/ Formycon"},{"orgOrder":0,"company":"Bioeq IP AG","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGFR A","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bioeq IP AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bioeq IP AG \/ Bioeq","highestDevelopmentStatusID":"12","companyTruncated":"Bioeq IP AG \/ Bioeq"}]

    Find Clinical Drug Pipeline Developments & Deals by Bioeq IP AG

    Menu

    Bioeq IP AG

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Bioeq IP AG

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Bioeq IP AG

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ranibizumab

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Recipient : Teva Pharmaceutical Industries

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            European Commission Approves FYB201/Ranivisio®1 (Ranivisio - Ranibizumab), a Biosimilar to Lucentis®2

                            Details : Ranivisio (ranibizumab) is indicated for the treatment of neovascular (wet) age-related macular degeneration, treatment of visual impairment due to diabetic macular oedema or choroidal neovascularization, proliferative diabetic retinopathy, as well as vi...

                            Brand Name : Ranivisio

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            August 29, 2022

                            Lead Product(s) : Ranibizumab

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Recipient : Teva Pharmaceutical Industries

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Bioeq IP AG

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Bioeq IP AG

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ranibizumab

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Recipient : Coherus Biosciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FDA Approves Coherus’ CIMERLI™ (ranibizumab-eqrn) as the First and Only Interchangeable Biosimilar to Luce...

                            Details : The COLUMBUS-AMD study, published in highly-regarded medical journal Ophthalmology, was the head-to-head study where CIMERLI (ranibizumab) met its primary endpoint of change from baseline in best corrected visual acuity (BCVA) at week 8 as compared to re...

                            Brand Name : Cimerli

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            August 02, 2022

                            Lead Product(s) : Ranibizumab

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Recipient : Coherus Biosciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Bioeq IP AG

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Bioeq IP AG

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ranibizumab

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Coherus Biosciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            MHRA’s Authorization for BIOEQ’s Biosimilar in the United Kingdom

                            Details : CIMERLI™ is contraindicated in patients with ocular or periocular infections or known hypersensitivity to ranibizumab products or any of the excipients in CIMERLI™. Hypersensitivity reactions may manifest as severe intraocular inflammation

                            Brand Name : Cimerli

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 06, 2022

                            Lead Product(s) : Ranibizumab

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Coherus Biosciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Bioeq IP AG

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Bioeq IP AG

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ranibizumab

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Recipient : Teva Pharmaceutical Industries

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            United Kingdom First to Grant Licence for Teva’s Ophthalmology Biosimilar Ongavia (ranibizumab)

                            Details : MHRA granted a licence for Ongavia® (ranibizumab), a biosimilar to Lucentis®*, for the treatment of (wet) age-related macular degeneration (AMD) and several other eye diseases, such as diabetic macular oedema and proliferative diabetic retinopathy.

                            Brand Name : Ongavia

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 17, 2022

                            Lead Product(s) : Ranibizumab

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Recipient : Teva Pharmaceutical Industries

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Bioeq IP AG

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Bioeq IP AG

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ranibizumab

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Formycon

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Polpharma Biologics Group Announces That Its Joint Venture Company Bioeq Has Submitted A Biologics License App...

                            Details : FYB201 (Ranibizumab) is used in treatment of various eye diseases in adults which cause damage to retina, thereby impairing vision. In these diseases, protein called VEGF causes excessive blood vessels to form within retina, resulting in a progressive lo...

                            Brand Name : FYB201

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            August 06, 2021

                            Lead Product(s) : Ranibizumab

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Formycon

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Bioeq IP AG

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Bioeq IP AG

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ustekinumab

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Recipient : Formycon

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Formycon and Bioeq Announce Launch of Phase III Study of FYB202, a Biosimilar Candidate for Stelara (Ustekinum...

                            Details : The aim of the randomized, double-blind, multi-center Phase III study is to demonstrate the comparability of FYB202 and the reference product Stelara(R) in terms of efficacy, safety and immunogenicity in patients with moderate to severe psoriasis vulgari...

                            Brand Name : FYB202

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 09, 2020

                            Lead Product(s) : Ustekinumab

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Recipient : Formycon

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth